Biotech, Pharma and International Payment Platforms Make End-of-the-Week Gains
MoneyGram International, which was featured on Tuesday, is back near the top of our Rippers list — up 18%. $MGI is an international payment platform in the midst of a transformation to move the business to a digital-first emphasis. It is joined by CRISPR company Intellia Therapeutics which jumped 11%. $NTLA is one of a few CRISPR stocks we highlighted on Rippers back in September, and we’ve written a longer feature about CRISPR stocks to keep an eye on. This week, stocks got a boost as news of positive vaccine trials came out Monday morning. As we mentioned Tuesday, some of the biggest gainers were companies from sectors trampled from the side effects of COVID-19. However, some of the biggest gainers were also just the biotechs and pharmas making the vaccine and COVID-19 treatments possible. Shares of $PFE rose on Monday and then fell throughout the week; $MRNA and $SRNE rose throughout the week. Meanwhile, other vaccine makers remained stagnant.
MoneyGram International, together with its subsidiaries, provides cross-border peer-to-peer payments and money transfer services in the United States and internationally.The company operates through two segments, Global Funds Transfer and Financial Paper Products. The Global Funds Transfer segment offers money transfer services and bill payment services primarily to unbanked and underbanked consumers through third-party agents, including retail chains, independent retailers, post offices, and other financial institutions; and digital solutions, such as moneygram.com, mobile solutions, digital partners, wallets, and account deposit services.The Financial Paper Products segment provides money orders to consumers through its agents and financial institutions under the MoneyGram brand and on a private label or co-branded basis with various agents and financial institutions; and official check outsourcing services for financial institutions.MoneyGram International, Inc. is based in Dallas, Texas. (From: StockAnalysis.com)